News

Joseph Rossano, MD, MPH, discusses the 56-week active-treatment period of the SCOUT-HCM trial, which demonstrated the sustainability of mavacamten’s effects.

New survey data from 42 countries show high antiviral adherence among people with hepatitis B, but 64% of those untreated receive no hepatitis B care.

Pharmacovigilance data on 328 pregnancies exposed to glecaprevir/pibrentasvir presented at AASLD 2026 showed no vertical transmission and no pattern of congenital anomalies.

Christie Ballantyne, MD, discusses his analysis of the CORALreef Lipids trial, highlighting enlicitide’s effects on LDL-C, ApoB, Lp(a), and non-HDL-C.

Jasmohan Bajaj, MD, MS, joins Nancy Reau, MD, and Kimberly Brown, MD, on who to screen for HE in clinic and how to prepare patients and families.

Gerard Criner, MD, reviews GOLD 2026 sessions on mucus plugs and inhaler technique, plus multimorbidity, exacerbation risk, and the 2027 GOLD Report.

ALTUS data show the multi-target HCC blood test score tracks tumor size, Milan status, and LI-RADS category rather than liver disease severity.

Dupilumab cut new or worsening allergies by 34% vs placebo in a 12-trial atopic dermatitis meta-analysis, suggesting it may slow the atopic march.

Lp(a)HORIZON and ZEUS hit their biomarker targets but not MACE. Stephen Greene, MD, and Muthiah Vaduganathan, MD, MPH, unpack both at AHA 2026.

Emma Guttman-Yassky, MD, discusses biomarker data showing rezpegaldesleukin's regulatory T-cell mechanism separates from placebo early.

Michelle O’Donoghue, MD, discusses the results of Part A of the TYDAL-TIMI 78 trial, demonstrating MAR001’s comparative efficacy to placebo.

Late-breaking ELSPIRE data show elafibranor normalized ALP in 85% of patients with PBC and ALP below 1.67 times ULN despite UDCA, vs 23% with placebo.

Liver stiffness, bilirubin, and symptoms can guide when to start second-line PBC therapy as ALP normalization becomes achievable for more patients.

Risankizumab improved skin clearance, itch, and quality of life through 52 weeks in pediatric psoriasis in the phase 3 OptIMMize-1 study.

Dave Singh, MD, discusses IL-33 inhibition for non-type 2 COPD, 2027 GOLD report refinements, and how to view biologics not yet in the GOLD algorithm.

In 3-year BE HEARD data, close to half of bimekizumab-treated HS patients reported no quality-of-life impact, regardless of baseline draining tunnel count.

Autumn Burnette, MD, hosts a new monthly allergy and immunology podcast from HCPLive, opening with an episode on hereditary angioedema.

Martina Porter, MD, of Beth Israel Deaconess Medical Center discusses unmet needs in HS and where oral povorcitinib fits among emerging options.

MAESTRO-NASH data show early liver fat reductions on MRI-PDFF predict biopsy-confirmed MASH resolution and fibrosis improvement with resmetirom.

Phase 2 data show zabopegdutide, a dual GLP-1/glucagon agonist, improved fibrosis and drove MASH resolution vs placebo at 48 weeks.

Juanita Mora, MD, of Chicago Allergy Center discusses strategies from boosters and antiviral prophylaxis to specialist counseling.

Stay updated with the latest healthcare breakthroughs, including 96-week durability data for GSK’s bepirovirsen in hepatitis B, and more.

The FDA approved asundexian with antiplatelet therapy after noncardioembolic ischemic stroke or high-risk TIA, based on OCEANIC-STROKE data.

Robert Rosenson, MD, discusses the long-term extension of the phase 3 PALISADE trial, which demonstrated plozasiran’s association with lower ApoC3 and fasting TG.

Most patients with type 2 COPD also have non-type 2 inflammation, shaping how clinicians may use targeted and anti-alarmin biologics, per Dave Singh, MD.

Clinicians at ACAAI 2026 will see late-breaking HAE, anaphylaxis, urticaria, and food allergy data, plus exclusive expert interviews.

Pavel Strnad, MD, discusses interim RestorAATion-2 data showing RNA editing with WVE-006 restored functional M-AAT and reduced Z-AAT in Pi*ZZ AATD.

Jörn Schattenberg, MD, discusses phase 2b data showing efinopegdutide improved MASH resolution and fibrosis vs placebo, with an open-label semaglutide arm.